Physician profile
Fei Cao
NPI 1598299687
$6,641.31
in general payments reported to CMS, 2019-2025
14 companies · $405 in 2025
The $405 reported for 2025 was less than what a typical Pain Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $4,524 · 2023: $722 · 2024: $875 · 2025: $405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,001.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,105.12 | 2022-2025 | Proclaim, Eterna |
| Spr Therapeutics, INC | $824.91 | 2022-2025 | Sprint Pns System |
| Nalu Medical, INC. | $448.01 | 2023-2024 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $328.46 | 2021-2025 | General - Pain Management |
| Tris Pharma INC | $205.81 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Nevro Corp. | $190.94 | 2022 | |
| Janssen Pharmaceuticals, INC | $150.00 | 2023 | Spravato |
| Averitas Pharma INC. | $136.37 | 2023-2024 | Qutenza |
| Tonix Medicines, INC. | $77.10 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $54.18 | 2025 | |
| Medtronic, INC. | $45.12 | 2022-2024 | Accurian |
| Grt US Holding, INC. | $35.04 | 2022 | |
| Curonix LLC | $21.06 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Globus Medical, INC. | $19.19 | 2025 | Senza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fei Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.